SCHEMBL15030529

SCHEMBL15030529

Cc1cccn(CC(=O)c2ccc(-c3cccnc3)cc2)c1=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MKNK1 Q9BUB5 6/20 0.48
▸ MKNK2 Q9HBH9 6/20 0.48
▸ MMP2 P08253 1/20 0.48
▸ MMP3 P08254 1/20 0.48
▸ MMP9 P14780 1/20 0.48
▸ MMP8 P22894 1/20 0.48
▸ MMP14 P50281 1/20 0.48
▸ MMP17 Q9ULZ9 1/20 0.48
▸ ALDH1A1 P00352 2/20 0.45
▸ KDM4E B2RXH2 1/20 0.45
▸ GRIN2B Q13224 1/20 0.44
▸ MAPT P10636 1/20 0.44
▸ SLC2A1 P11166 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ GRM2 Q14416 1/20 0.41
▸ CDC25A P30304 1/20 0.41
▸ CDC25B P30305 1/20 0.41
▸ DEGS1 O15121 1/20 0.40
▸ USP1 O94782 1/20 0.40
▸ WDR48 Q8TAF3 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15030524 0.88 ALDH1A1 (0.48) MMP8MMP14ALDH1A1KDM4EGRIN2B
SCHEMBL15030557 0.86 PLOD2 (0.47) MMP2MMP3MMP9MMP8MMP14
SCHEMBL16806629 0.79 KDM4E (0.54) ALDH1A1KDM4EMAPTSMN1; SMN2THRB
SCHEMBL15030297 0.78 ALDH1A1 (0.53) ALDH1A1KDM4EGRIN2BMAPTSMN1; SMN2
SCHEMBL15030298 0.78 RXFP1 (0.60) ALDH1A1KDM4EGRIN2BMAPTSMN1; SMN2
SCHEMBL15030482 0.78 MEN1 (0.54) ALDH1A1KDM4EMAPTSMN1; SMN2THRB
SCHEMBL15030280 0.77 ALDH1A1 (0.52) ALDH1A1KDM4EMAPTSMN1; SMN2THRB
SCHEMBL15030485 0.75 MAPT (0.52) ALDH1A1KDM4EMAPTSMN1; SMN2THRB
SCHEMBL15030415 0.75 ALDH1A1 (0.56) ALDH1A1KDM4EMAPTTHRB
SCHEMBL15030532 0.75 KDM4E (0.50) ALDH1A1KDM4EMAPTSMN1; SMN2THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10000476-B2 Pyridone derivative, pharmaceutical containing the same and methods of use thereof KAKEN PHARMACEUTICAL CO., LTD. (JP) 2018-06-19 — — US disclosed
US-10000476-B2 Pyridone derivative, pharmaceutical containing the same and methods of use thereof KAKEN PHARMACEUTICAL CO., LTD. (JP) 2018-06-19 — — US disclosed
US-20160340349-A1 PYRIDONE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME KAKEN PHARMACEUTICAL CO., LTD. (JP) 2016-11-24 — — US disclosed
US-20160340349-A1 PYRIDONE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME KAKEN PHARMACEUTICAL CO., LTD. (JP) 2016-11-24 — — US disclosed
US-9447072-B2 Pyridone derivative and pharmaceutical containing same KAKEN PHARMACEUTICAL CO., LTD. (JP) 2016-09-20 — — US disclosed
US-9447072-B2 Pyridone derivative and pharmaceutical containing same KAKEN PHARMACEUTICAL CO., LTD. (JP) 2016-09-20 — — US disclosed
US-20160168540-A1 COMPOSITION FOR MAINTAINING PLATELET FUNCTION KAKEN PHARMACEUTICAL CO., LTD. (JP) 2016-06-16 — — US disclosed
US-20160168540-A1 COMPOSITION FOR MAINTAINING PLATELET FUNCTION KAKEN PHARMACEUTICAL CO., LTD. (JP) 2016-06-16 — — US disclosed
EP-3006029-A1 COMPOSITION FOR MAINTAINING PLATELET FUNCTION Kaken Pharmaceutical Co., Ltd. (JP) 2016-04-13 — — EP disclosed
US-20150166506-A1 PYRIDONE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME KAKEN PHARMACEUTICAL CO., LTD. (JP) 2015-06-18 — — US disclosed
US-20150166506-A1 PYRIDONE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME KAKEN PHARMACEUTICAL CO., LTD. (JP) 2015-06-18 — — US disclosed
WO-2013085017-A1 PYRIDONE DERIVATIVE AND MEDICINE CONTAINING SAME 科研製薬株式会社 (JP) 2013-06-13 — — WO disclosed
WO-2013085016-A1 PYRIDONE DERIVATIVE AND MEDICINE CONTAINING SAME 科研製薬株式会社 (JP) 2013-06-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160340349-A1 PYRIDONE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME PLPBP, PDXK, PNPO MKNK1 2613/4885MKNK2 2221/4885MMP2 3807/4885
US-10000476-B2 Pyridone derivative, pharmaceutical containing the same and methods of use thereof PNPO, PDXK, PLPBP MKNK1 3061/4885MKNK2 2588/4885MMP2 3288/4885
US-20160168540-A1 COMPOSITION FOR MAINTAINING PLATELET FUNCTION PF4, F2, PFKP MKNK1 2205/4885MKNK2 1701/4885MMP2 3378/4885
US-20150166506-A1 PYRIDONE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME PLPBP, PDXK, PNPO MKNK1 2613/4885MKNK2 2221/4885MMP2 3807/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback